Stateside's Canadian Microcap Board Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Stateside's Canadian Microcap Board

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: downandout	4/5/2016 10:12:51 AM
	Read Replies (1) of 1728

BriaCell hopes to begin BriaVax trial this quarter 2016-04-05 07:09 PT - News Release Dr. Saeid Babaei reports BRIACELL TARGETING LAUNCH OF ITS PHASE I/II CLINICAL TRIAL DURING CURRENT QUARTER BriaCell Therapeutics Corp. has provided an update in regard to the planned timing of its phase I/II clinical trial for up to 24 late-stage cancer patients. BriaCell has spent a great deal of time and effort in preparing for the anticipated Phase I/II clinical trial. Based upon the Company's current discussions with its partners, BriaCell believes it will be in a position to launch the trial within this current quarter. The Company is working diligently on a number of key initiatives including completion of its vaccine manufacturing, coordinating clinical sites, and finalizing its Contract Research Organization (CRO). The Company hopes to provide further updates on all fronts in the near future. Dr. Saeid Babaei, Chairman of the Board noted, "BriaCell is now in the final stages of preparations for its clinical trial with its lead cancer vaccine, BriaVax{A }. BriaCell is excited about entering the clinic in order to dose patients and hopefully expand upon its Phase I results. Additionally, the trial will serve to advance BriaCell's R&D platform through utilizing future BriaVax{A } data in complementing its existing gene signature announced last week. We will continue to take steps to work with partners and contractors who can meet our demanding standards and timelines." Manufacturing of the vaccine is nearing completion at the facilities of BriaCell's partner, University of California Davis. As prior noted, UC Davis is manufacturing compliant cGMP-grade BriaVax{A } which will be used in dosing patients during the upcoming trial. The Company has already been notified that several BriaVax batches have been completed, and hopes to report further on this matter in the coming weeks. Upon receiving FDA authorization 5 months ago, BriaCell embarked on identifying a suitable CRO partner in order to facilitate the trial. The Company is at the final stages of negotiations and hopes to report further on this within the coming weeks. BriaCell has been in discussions with potential sites at which it would recruit and dose patients during its Phase I/II. These sites are primarily university-hospitals with large patient populations who might be matches for BriaCell's trial. BriaCell hopes to update further on this matter in the near future. We seek Safe Harbor. © 2016 Canjex Publishing Ltd. All rights reserved.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next